There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at.
For those who don't know what the patent…
Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own one of the large cap biotechs, you are betting that…
There are already some ASX companies experiencing a better FY26 than FY25. It may only be 3 and a half months into the new financial year, but some of the…
When we last wrote about Clarity Pharmaceuticals (ASX:CU6), in July last year, it was a multi-billion dollar company, less than 3 years after an IPO that valued the company at…
6 of the best performing ASX All Ords stocks in the past year
Clarity Pharmaceuticals (ASX:CU6)
Clarity is a late-stage clinical biotech, testing its Targeted Copper Theranostics (TCT) technology in…